Johnson & Johnson (JNJ) Receives a Buy from Credit Suisse

By Austin Angelo

Credit Suisse analyst Matt Miksic maintained a Buy rating on Johnson & Johnson (JNJResearch Report) today and set a price target of $156. The company’s shares closed last Monday at $129.64.

According to TipRanks.com, Miksic is a 5-star analyst with an average return of 16.1% and a 76.5% success rate. Miksic covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Edwards Lifesciences.

Currently, the analyst consensus on Johnson & Johnson is a Moderate Buy with an average price target of $152, representing a 17.0% upside. In a report released today, Goldman Sachs also maintained a Buy rating on the stock with a $169 price target.

See today’s analyst top recommended stocks >>

Based on Johnson & Johnson’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $20.58 billion and net profit of $5.61 billion. In comparison, last year the company earned revenue of $20.81 billion and had a net profit of $3.95 billion.

Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of JNJ in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.